IF 2

Pharmacy Pub Date : 2025-05-21 DOI: 10.3390/pharmacy13030072

Jennie B Jarrett, Abigail T Elmes-Patel, Sheila M Allen, Marlowe Djuric Kachlic, Allison E Schriever, Tara P Driscoll, Ara Tekian, Jeffrey J H Cheung, Edward Podsiadlik, Stuart T Haines, Alan Schwartz

{"title":"Longitudinal Preceptor Assessment of Entrustable Professional Activities Across Introductory and Advanced Pharmacy Practice Experiences.","authors":"Jennie B Jarrett, Abigail T Elmes-Patel, Sheila M Allen, Marlowe Djuric Kachlic, Allison E Schriever, Tara P Driscoll, Ara Tekian, Jeffrey J H Cheung, Edward Podsiadlik, Stuart T Haines, Alan Schwartz","doi":"10.3390/pharmacy13030072","DOIUrl":"10.3390/pharmacy13030072","url":null,"abstract":"The objective was to evaluate the growth in pharmacy student performance in entrustable professional activity (EPA) assessments across the experiential curriculum based on preceptor assessments on an entrustment-supervision (ES) scale. This retrospective cohort study used assessments based on the 2016 American Association of Colleges of Pharmacy Core EPAs and an expanded ES scale during introductory and advanced pharmacy practice experiences (IPPEs/APPEs) in the third and fourth professional years from fall 2020 to fall 2023. The primary outcome was the change in ES level, assessed by preceptors over time. The secondary outcomes were growth rates across types of experiences, training environments, and experience order. A conditional growth curve model and ordinal mixed effects model were used to demonstrate discrete entrustment decisions. A total of 509 students received 12,426 assessments by 557 preceptors. Raw ES levels and unconditional growth curves for EPA show increases in entrustability from years P3 to P4. Comparing care settings, there was lower entrustment in inpatient than outpatient settings and at academic medical centers than other settings. There were no significant differences in ES levels regardless of which IPPE was taken first. However, when the first APPE was an inpatient medicine experience, ES levels across APPEs for EPA 3 were higher when compared to ambulatory care as the first APPE, and they were higher for EPA 5 when compared to community pharmacy as the first APPE. Paired with ES scales, EPAs can be integrated into pharmacy experiential curricula to demonstrate longitudinal growth in student entrustment.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ustekinumab in the Treatment of Crohn's Disease-A Narrative Review on Clinical Efficacy and Safety Profile. Ustekinumab治疗克罗恩病的临床疗效和安全性综述

IF 2

Pharmacy Pub Date : 2025-05-21 DOI: 10.3390/pharmacy13030073

Dawid Piecuch, Edyta Hańczyk, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Karolina Kornatowska

{"title":"Ustekinumab in the Treatment of Crohn's Disease-A Narrative Review on Clinical Efficacy and Safety Profile.","authors":"Dawid Piecuch, Edyta Hańczyk, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Karolina Kornatowska","doi":"10.3390/pharmacy13030073","DOIUrl":"10.3390/pharmacy13030073","url":null,"abstract":"Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that leads to significant deterioration in patients' quality of life. Biologic therapy, including the use of ustekinumab (UST), is a modern approach to treating the moderate to severe form of CD, especially in patients refractory to traditional treatments. UST, which acts as an interleukin IL-12 and IL-23 antagonist, has shown high efficacy in reducing inflammation, improving quality of life, and promoting mucosal regeneration and fistula healing. However, the use of biologic therapies, such as UST, has challenges related to the timing of treatment and patient response, including the problem of immunogenicity. To determine the clinical efficacy and safety profile of UST in the treatment of CD, a review of the literature published in the PubMed database over the last 5 years was conducted. After excluding articles that did not meet the inclusion criteria, we analyzed 42 clinical studies. The review discusses the available data on the efficacy and safety of UST, as well as its comparison with other biologic therapies, such as infliximab and adalimumab. UST, although not significantly greater to adalimumab, has lower immunogenicity and higher treatment retention. The therapeutic value of UST is also confirmed by biosimilars such as ABP 65 and FYB202, which show comparable efficacy and safety profile. The analysis of predictive biomarkers, such as serum drug levels and baseline eosinophil levels, could be an important element in the future personalization of CD treatment. The review's findings point to the importance of further research to improve the tailoring of therapies to individual patients and improve long-term treatment outcomes.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Affinity Group Experiences in Pharmacy Education: A Pilot Study. 亲和团体经验在药学教育中的初步研究。

IF 2

Pharmacy Pub Date : 2025-05-20 DOI: 10.3390/pharmacy13030070

Elise Moore, Caroline Gaither, Olihe Okoro, Laura Palombi, L'Aurelle A Johnson

{"title":"Affinity Group Experiences in Pharmacy Education: A Pilot Study.","authors":"Elise Moore, Caroline Gaither, Olihe Okoro, Laura Palombi, L'Aurelle A Johnson","doi":"10.3390/pharmacy13030070","DOIUrl":"10.3390/pharmacy13030070","url":null,"abstract":"This study aims to examine the current wellbeing among pharmacy students in underrepresented groups (URGs) and investigate the impact on having access to affinity groups. A survey was distributed to students in April and May 2023, at a Midwestern College of Pharmacy, centering around diversity, equity, inclusion, and accessibility (DEIA) efforts and their impact on student wellbeing and experiences with the college-supported affinity groups. Student responses were analyzed using descriptive statistics. Sixty-five (75%) of the eighty-six students who completed the survey identified with at least one URG. First-generation students (n = 36), underrepresented racial/ethnic groups (n = 24), and LGBTQ+ (n = 13) were the three most prominent groups. Twenty-seven percent (n = 23) of students belonged to multiple URGs. Among the students in URGs, three out of four experienced distress. The students in URGs experienced distress at a higher rate compared to their peers in all categories. Twenty percent (n = 16) of students did not agree that there was equitable treatment on campus. This rate was higher among students in URGs compared to their peers. Eighty-three percent (n = 52) of individuals who did not participate in an affinity group recognized there was a need. Among individuals who did not participate, nearly half identified with a URG. Pharmacy students, especially those in URGs, may benefit from additional interventions by pharmacy schools to improve the offering and visibility of supportive services. Providing URG-centered resources addresses the gap between the wellbeing and academic experience of pharmacy students in URGs compared to their peers.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming Pharmacy Students' Perceptions of Diabetes: An Innovative Teaching Approach Using Patient Interviews and Photovoice. 转变药学学生对糖尿病的认知：采用病人访谈与影像语音的创新教学方法。

IF 2

Pharmacy Pub Date : 2025-05-20 DOI: 10.3390/pharmacy13030069

Jenifer Santos, Manuel Machuca

{"title":"Transforming Pharmacy Students' Perceptions of Diabetes: An Innovative Teaching Approach Using Patient Interviews and Photovoice.","authors":"Jenifer Santos, Manuel Machuca","doi":"10.3390/pharmacy13030069","DOIUrl":"10.3390/pharmacy13030069","url":null,"abstract":"This study evaluated an innovative teaching methodology in a Health Anthropology course for Pharmacy students aimed at transforming their perceptions of diabetes. Through patient interviews and the photovoice technique, students gained deeper insights into the psychosocial aspects of the disease. Surveys were administered at the beginning, midpoint, and end of the course to assess shifts in students' perspectives. The results revealed a significant change, with students evolving from a primarily biomedical view to a more holistic understanding, emphasizing the patient's lived experience. Additionally, students responded positively to the innovative approach, citing enhanced motivation and learning, though some noted the methodology's demanding workload. This teaching intervention fostered empathy and a broader perspective on the challenges faced by patients living with diabetes, supporting a more patient-centered and humanistic approach to healthcare. Despite the positive feedback, there was some uncertainty about whether this methodology could be applied to other subjects within the Pharmacy curriculum.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming Care: Exploring Consumer and Pharmacist Perceptions of Expanded Pharmacy Practice in Rural and Remote Communities. 转变护理：探索消费者和药剂师的观念扩大药房实践在农村和偏远社区。

IF 2

Pharmacy Pub Date : 2025-05-20 DOI: 10.3390/pharmacy13030071

Selina Taylor, Shelby Joyce, Ruby Schembri, Josh Swain, Rachael Turiano, Beverley D Glass

{"title":"Transforming Care: Exploring Consumer and Pharmacist Perceptions of Expanded Pharmacy Practice in Rural and Remote Communities.","authors":"Selina Taylor, Shelby Joyce, Ruby Schembri, Josh Swain, Rachael Turiano, Beverley D Glass","doi":"10.3390/pharmacy13030071","DOIUrl":"10.3390/pharmacy13030071","url":null,"abstract":"Accessing essential healthcare services presents a challenge for consumers living in rural and remote communities, leading to higher rates of chronic disease and poorer health outcomes. Community pharmacists are well positioned to address this lack of access; thus, this study aimed to explore the perceptions of rural and remote consumers and pharmacists with respect to community pharmacists expanding their services in these communities. Qualitative, semi-structured interviews were undertaken with consumers and pharmacists recruited from community pharmacies in the far north, north west, and central west Queensland. The Consolidated Framework for Implementation Research guided question development, with the responses deductively coded and thematically analysed. Thirteen pharmacists and twenty-three consumers were interviewed, with both groups citing the benefit of reduced wait times. Key barriers were pharmacist workload, time constraints, inadequate infrastructure, and limited consumer awareness of services. Pharmacists highlighted the need for better reimbursement models and professional collaboration, while consumers valued accessibility and convenience but were concerned about the costs of services. This study has highlighted the benefits of expanded pharmacy services as perceived by the key stakeholders: consumers and pharmacists. However, future research investigating a larger sample in more rural and remote locations is needed to ensure the successful implementation of sustainable funding models to deliver better access and health outcomes for consumers in these communities.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Declines in Tapentadol Use in the US but Pronounced Regional Variation. 他他多的使用在美国下降，但明显的地区差异。

IF 2

Pharmacy Pub Date : 2025-05-14 DOI: 10.3390/pharmacy13030067

Ching Y Low, Kenneth L McCall, Brian J Piper

{"title":"Declines in Tapentadol Use in the US but Pronounced Regional Variation.","authors":"Ching Y Low, Kenneth L McCall, Brian J Piper","doi":"10.3390/pharmacy13030067","DOIUrl":"10.3390/pharmacy13030067","url":null,"abstract":"Background: Tapentadol is an atypical opioid with a dual mechanism as a mu agonist and norepinephrine reuptake inhibitor. This study characterized tapentadol use in the United States (US) using three databases.Methods: Drug distribution data from 2010 to 2020 were extracted from the Drug Enforcement Administration (DEA)'s Automated Reports and Consolidated Orders System (ARCOS), including use per region (mg/person) and business activity (i.e., pharmacy). Tapentadol prescription claims from the Medicare and Medicaid programs for 2010-2020 were also examined.Results: The distributed amount of tapentadol was 3.5 tons in 2020. Distribution was over twice as high in southern (South Atlantic = 29.0 mg/person, East South Central = 28.8) relative to Pacific (12.9) or New England (12.8) states. Tapentadol use decreased nationally between 2012 and 2020 by -53.8%. Adult diabetes prevalence was significantly associated with tapentadol distribution in 2012 (r(50) = +0.44, p < 0.01) and 2020 (r(50) = +0.28, p < 0.05). Tapentadol prescribing to Medicaid patients declined -55.2% from the peak year, 2011, until 2020. Tapentadol prescribed by Nurse Practitioners accounted for over one-sixth (18.0%) of 2019 in Medicare.Conclusions: There has been a substantial decline over the past decade in tapentadol distribution and prescribing. However, the substantial regional differences may warrant further attention by opioid stewardship programs.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferences of Hospital Pharmacists for the Different Attributes of Intravitreal Treatments for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Spain: The SEEKING Study. 西班牙医院药师对新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿玻璃体内不同属性治疗的偏好：seek研究

IF 2

Pharmacy Pub Date : 2025-05-14 DOI: 10.3390/pharmacy13030068

José Luis Poveda, Pablo Arnáiz, Silvia López, Belén Muñoz, Anxo Fernández-Ferreiro

{"title":"Preferences of Hospital Pharmacists for the Different Attributes of Intravitreal Treatments for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Spain: The SEEKING Study.","authors":"José Luis Poveda, Pablo Arnáiz, Silvia López, Belén Muñoz, Anxo Fernández-Ferreiro","doi":"10.3390/pharmacy13030068","DOIUrl":"10.3390/pharmacy13030068","url":null,"abstract":"The process of evaluation and selection of drugs in Spain is currently changing, with hospital pharmacists (HPs) having a growing relevance. This cross-sectional observational study aimed to assess HPs' preferences for different hypothetical intravitreal treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Best corrected visual acuity (BCVA), ocular adverse events (AE), annual drug cost, available presentation, and mechanisms of action (MoA) were the selected attributes. A conjoint analysis was used. Ninety-one HPs completed the study. The mean (SD) age was 39.2 (10.2) years, 60.4% were female, and the mean (SD) time of experience as HP was 12.6 (8.3) years. For nAMD treatments, BCVA (38.6%) and ocular AE (27.3%) were the most important attributes, while annual drug cost (16.3%), available presentation (11.1%), and MoA (6.7%) were not as important. For DME drugs, BCVA (44.6%) and ocular AE (25.5%) were the most significant factors; annual drug cost (17.9%), the drug's available presentation (7.3%), and MoA (4.8%) were not considered to be as crucial. Preferences were comparable independent of HP experience. Effectiveness and safety were the most important attributes when choosing a drug. Comprehending the significant characteristics for HPs could potentially improve their collaborative function within multidisciplinary teams involved in intravitreal treatments.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Preceptors' Toolkit for Working with Struggling Pharmacy Students. 与苦苦挣扎的药学学生一起工作的导师工具包。

IF 2

Pharmacy Pub Date : 2025-05-02 DOI: 10.3390/pharmacy13030066

Christina L Mnatzaganian, Caitlin M Gibson, Lisa Kipper, Charlene R Williams, Tram B Cat

引用次数: 0

Ketoprofen Lysine Salt Versus Corticosteroids in Early Outpatient Management of Mild and Moderate COVID-19: A Retrospective Study. 酮洛芬赖氨酸盐与皮质类固醇在轻中度COVID-19早期门诊治疗中的回顾性研究

IF 2

Pharmacy Pub Date : 2025-05-01 DOI: 10.3390/pharmacy13030065

Domenica Francesca Mariniello, Raffaella Pagliaro, Vito D'Agnano, Angela Schiattarella, Fabio Perrotta, Andrea Bianco

{"title":"Ketoprofen Lysine Salt Versus Corticosteroids in Early Outpatient Management of Mild and Moderate COVID-19: A Retrospective Study.","authors":"Domenica Francesca Mariniello, Raffaella Pagliaro, Vito D'Agnano, Angela Schiattarella, Fabio Perrotta, Andrea Bianco","doi":"10.3390/pharmacy13030065","DOIUrl":"10.3390/pharmacy13030065","url":null,"abstract":"Background: Accelerating recovery and preventing the progression to more severe outcomes for patients with coronavirus disease 2019 (COVID-19) is of paramount importance. Non-steroidal anti-inflammatory agents (NSAIDs) have been widely adopted in the international recommendations for non-severe COVID-19 management. Among NSAIDs, evidence about the efficacy of ketoprofen lysin salt (KLS) in the treatment of non-severe COVID-19 has not been reported. Methods: This retrospective study compared the outcomes of 120 patients with mild to moderate COVID-19 treated at home with KLS between March 2021 and May 2023 compared with the outcomes of 165 patients who received corticosteroids. The outcomes included hospitalization, the need for oxygen supplementation, clinical recovery from acute COVID-19, and time to negative swabs. Results: Symptoms persisted in a lower percentage of patients in the KLS group compared to the corticosteroids group (p < 0.0001) and for a shorter period (p = 0.046). We found 6 patients (5%) in the KLS group were hospitalized compared to 45 (27%) in the corticosteroids group (p < 0.001). A higher percentage of patients in the corticosteroids group require oxygen administration (p < 0.001). In addition, patients taking corticosteroids showed a longer viral shedding period compared to those taking KLS (p = 0.004). A final multivariate analysis suggests that KLS might reduce hospitalization risk, the need for oxygen supplementation, and the persistence of post-COVID-19 symptoms when compared to an oral corticosteroid after adjusting for significant co-variables. Conclusions: KLS might have a positive effect on clinical recovery in non-severe COVID-19 patients. A comparison with other NSAIDs in terms of difference in efficacy and safety should be investigated in further trials.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Power of Active Listening to Address Medication Non-Adherence During Care Transition: A Case Report of a Polypharmacy Patient with Type 2 Diabetes. 积极倾听解决护理过渡期间药物依从性问题的力量：1例多药合并2型糖尿病患者报告。

IF 2

Pharmacy Pub Date : 2025-04-30 DOI: 10.3390/pharmacy13030064

Léa Solh Dost, Giacomo Gastaldi, Marie P Schneider

引用次数: 0

Pharmacy最新文献